Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leukemia following Hodgkin's disease.
Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pedersen D, Band P, Assouline D, et al. Kaldor JM, et al. Among authors: van leeuwen fe. N Engl J Med. 1990 Jan 4;322(1):7-13. doi: 10.1056/NEJM199001043220102. N Engl J Med. 1990. PMID: 2403650 Free article. Clinical Trial.
Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.
van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JM, Somers R. van Leeuwen FE, et al. Among authors: van den belt dusebout aw. J Natl Cancer Inst. 1995 Oct 18;87(20):1530-7. doi: 10.1093/jnci/87.20.1530. J Natl Cancer Inst. 1995. PMID: 7563187
Risk of leukemia following treatment for non-Hodgkin's lymphoma.
Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM, et al. Travis LB, et al. Among authors: van leeuwen fe. J Natl Cancer Inst. 1994 Oct 5;86(19):1450-7. doi: 10.1093/jnci/86.19.1450. J Natl Cancer Inst. 1994. PMID: 8089863
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, van Heerde P, Somers R. van Leeuwen FE, et al. Among authors: van heerde p, van den belt dusebout aw, van kerkhoff eh. J Clin Oncol. 1994 Feb;12(2):312-25. doi: 10.1200/JCO.1994.12.2.312. J Clin Oncol. 1994. PMID: 8113838
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, Pinedo HM, Somers R. van Leeuwen FE, et al. Among authors: van den belt dusebout aw, van kerkhoff eh. J Clin Oncol. 1994 May;12(5):1063-73. doi: 10.1200/JCO.1994.12.5.1063. J Clin Oncol. 1994. PMID: 8164031
Second cancers among long-term survivors of non-Hodgkin's lymphoma.
Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, Adami J, Gospodarowicz M, Wacholder S, Inskip P, et al. Travis LB, et al. Among authors: van leeuwen fe. J Natl Cancer Inst. 1993 Dec 1;85(23):1932-7. doi: 10.1093/jnci/85.23.1932. J Natl Cancer Inst. 1993. PMID: 8230284
Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.
van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, Delemarre JF, Somers R. van Leeuwen FE, et al. Among authors: van den belt dusebout aw, van kerkhoff eh. J Clin Oncol. 1993 Mar;11(3):415-24. doi: 10.1200/JCO.1993.11.3.415. J Clin Oncol. 1993. PMID: 8445415
504 results